Patent · US Active

Virus

US12016949B2 · kind B2 · utility

0Cited by
6References
12Claims
0Family size

Assignee

Inventor

Key dates

Filing dateJan 5, 2018
Grant dateJun 25, 2024
Priority date
Expiry dateJun 9, 2040

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY02A50/30
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The invention is in the field of delivery of transgenes to target cells using viral vectors, particularly in the field of gene therapy. Compositions have been identified which allow for oral administration of viral particles, particularly adenoviral particles.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.